Filtered By:
Condition: Pulmonary Hypertension
Infectious Disease: COVID-19
This page shows you your search results in order of date.
Order by Relevance | Date
Total 36 results found since Jan 2013.
New Janssen Initiative Aims to Advance Equitable Care and Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)
TITUSVILLE, N.J., March 31, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial focus on reaching Black Americans, who are more than twice as likely to be impacted by PAD.1 Janssen has joined forces with leading professional associations, healthcare systems and community organizations to advance equitable care for individuals and communities placed at an...
Source: Johnson and Johnson - March 31, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Controversies over the impact of the COVID-19 pandemic on patients with Pulmonary Arterial Hypertension
This study is a retrospective analysis of our PAH patients treated in 2020 compared to the dynamics of the last 12 years. We had 48 PAH patients, 51.72±16.64 years, 72.91% female. All patients had chronic anticoagulant therapy(58.33%) and/or antiplatelet; 33.33% had long term oxygen therapy. Three patients with secondary forms were confirmed with COVID-19, all hospitalized (6.25% infection rate versus 3.29% in general). One patient died(75 years with scleroderma, stroke), two patients were cured (mild forms). In total only three patients died in 2020. Surprisingly, compared with 2008-2019 (101 patients/ 41 deaths, 3...
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Bertici, N. S., Dobrescu, L., Pislaru, L., Marincu, I. Tags: Pulmonary hypertension Source Type: research
A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis
Curr Issues Mol Biol. 2021 Sep 22;43(3):1212-1225. doi: 10.3390/cimb43030086.ABSTRACTThe coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Most SARS-CoV-2 infections are mild or even asymptomatic. However, a small fraction of infected individuals develops severe, life-threatening disease, which is caused by an uncontrolled immune response resulting in hyperinflammation. However, the factors predisposing individuals to severe disease remain poorly understood. Here, we show that levels of CD47, which is known to mediate immune escape in cancer and virus-infected cells, are elevated in SARS-CoV-2-infected ...
Source: Current Issues in Molecular Biology - October 26, 2021 Category: Molecular Biology Authors: Katie-May McLaughlin Denisa Bojkova Joshua D Kandler Marco Bechtel Philipp Reus Trang Le Florian Rothweiler Julian U G Wagner Andreas Weigert Sandra Ciesek Mark N Wass Martin Michaelis Jindrich Cinatl Source Type: research
